SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is trending due to significant market volatility triggered by conflicting reports regarding a potential wind-down of the U.S. conflict with Iran, prompting intense community debate over whether this signals a genuine de-escalation or a tactical market pump. Traders are actively discussing the impact of these geopolitical headlines on energy costs, the potential for a short squeeze following recent sell-offs, and skepticism toward anonymous sources fueling overnight price swings.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as shareholders weigh a cryptic message from CEO Dr. Patrick Soon-Shiong about "strengthening the balance sheet" and "recharging for global expansion," which has sparked intense debate over whether it signals non-dilutive funding or future share dilution. The community is actively discussing the potential for international partnerships, particularly in the Middle East and Europe, while expressing frustration over ongoing short-seller activity and legal challenges.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is capturing significant market attention as a unique, permissionless brand driven by an unusually active community that focuses on real-world utility and product development rather than standard crypto hype. Enthusiasts are actively rallying behind its various grassroots initiatives, including apparel, food products, and lifestyle events, which they argue distinguishes the project from typical short-term speculative assets.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing heightened market volatility as investors weigh intense geopolitical tensions in the Middle East against ongoing concerns regarding delivery growth and executive turnover. While some community members are betting on a potential bounce fueled by rumors of a SpaceX IPO, others remain skeptical, focusing on the company's high valuation and internal leadership changes.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is trending due to heightened community speculation surrounding a potential SpaceX IPO and the company's recent operational updates, including a strategic partnership with Mu-G Technologies for microgravity missions. While bulls highlight the stock's low float and potential for a short squeeze alongside broader space sector growth, bears remain skeptical, citing leadership turnover and a lack of revenue as significant red flags.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing intense community debate as the stock experiences high-beta volatility correlated with Bitcoin's recent price action. Traders are actively clashing over the company's aggressive accumulation strategy and persistent share dilution, with bulls highlighting long-term conviction while bears point to downside risks and potential over-leverage.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is facing significant market volatility and community debate as investors weigh the potential impact of the pending Clarity Act against macroeconomic pressures and ongoing token supply concerns. While some traders are aggressively accumulating on dips, citing long-term institutional adoption and integration potential, others are increasingly frustrated by persistent price stagnation and the frequent dilution from scheduled supply unlocks.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant downward pressure as investors weigh potential memory sector headwinds, including AI efficiency developments, alongside broader market anxiety surrounding geopolitical tensions. The community is actively debating whether this pullback represents a fundamental shift in the cyclical demand for memory chips or a tactical entry point for long-term investors following recent earnings strength.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy is trending as investors digest an independent resource estimate of 13 billion barrels of oil in the Jameson Land Basin and recent strategic partnerships, including a collaboration with Halliburton for drilling operations. While the community is actively debating the potential of this Arctic energy play against its high-risk profile and market valuation, many are focused on its recent Nasdaq debut and speculation surrounding future drilling catalysts.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing significant volatility driven by market skepticism regarding shifting reports on the U.S. military strategy in Iran and the status of the Strait of Hormuz. Community sentiment is deeply divided, with many traders discussing aggressive short-selling and cautioning against 'pump-and-dump' volatility fueled by conflicting geopolitical headlines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of "Hold" from Analysts

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, MarketBeat.com reports. One equities research...

KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 600.0% in March

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,830,724 shares...

KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday

KALA BIO (NASDAQ:KALA) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...

KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) saw a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 975,765 shares, a growth...

AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. $KALA, $TGNT, $DOMO, $TSSI, $CYN, $AUNA, $VACHU

<ul class="summary-bullets"><li>Researgency enables firms to deploy AI tools for research, clinical trials, managing regulatory documents, and tracking drug safety.</li><li>Earlier this month, KALA signed a platform development and exclusive license agreement with Younet AI for Researgency.</li><li>The company said that while it will provide the AI platform, clients retain full control and ownership of their data.</li></ul>Shares of KALA BIO Inc. (KALA) shed most of their early gains to trade 25% higher on Wednesday, after the biotech company said it expects to ship its first commercial artificial intelligence product, the Researgency.ai platform, within 14 days.Researgency enables biotech and pharmaceutical companies to design and deploy AI tools to monitor research, support clinical trials, manage regulatory documents, track drug safety, and prepare commercial launch materials.The company said the platform is now fully live following a rebrand and is designed to deploy specialized AI agents to automate complex, repetitive tasks in drug development.“We are building the Palantir for biotech. Our first agent ships in 14 days, and our team is fired up. This is the beginning of something big,” said Avi Minkowitz, CEO of Kala.&nbsp;<h2 class="st-heading-2">Partnership With Younet AI To Develop Researgency</h2>Earlier this month, KALA signed a platform development and exclusive license agreement with Younet AI for Researgency. The agreement grants KALA access to the platform for an initial 12-month period, with the option to extend in one-year terms.KALA will provide the AI platform, specialized biomedical agents, and ongoing optimization, while clients retain full control and ownership of their data. The company said the platform targets small and mid-sized biotech firms seeking secure AI tools without relying on public AI services.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/KALA_jpg_f4e658a281.webp" alt="KALA.jpg">One user expects the stock to climb above $1 this week. It is currently at $0.36.<stembedurl>https://stocktwits.com/Ozunoy/message/647231891</stembedurl>Another user believes the development is “huge,” and that the company is “just getting started.”<stembedurl>https://stocktwits.com/jengtap/message/647229239</stembedurl><a href="https://stocktwits.com/symbol/KALA">KALA shares</a> have shed around 34% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-jumps-barclays-says-market-is-underestimating-opportunity-from-new-products/cZdr3RoRIJH">HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating&nbsp;Opportunity From New Products</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

Why Did KALA Stock Surge 25% Today?

KALA BIO Inc company said that it is ready to deploy its new AI platform, Researgency, within 14 days.

Equity

The company said that it is ready to deploy its new AI platform, Researgency, within 14 days.

KALA BIO, Inc. (NASDAQ:KALA) Given Average Rating of "Hold" by Analysts

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has been assigned a consensus rating of "Hold" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One...

<ul class="summary-bullets"><li>A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.</li><li>A two-stage preferred stock deal supplies up to $6 million to stabilize operations and restructure debts.</li><li>New turnaround-focused leadership was appointed as part of the recovery plan.</li></ul>Kala Bio surged 22% after hours on Tuesday after the company disclosed a rescue financing agreement that temporarily stabilizes its operations and averts a pending asset seizure by its lender. The move marks the company's reversal since September, when its eye disease therapy KPI-012 failed a Phase 2 trial, triggering a roughly 90% collapse in the stock and a wave of analyst downgrades.<h2 class="st-heading-2">Emergency Financing Steps In After Default</h2>The after-hours rally followed Kala’s filing detailing a sequence of events that began on Sept. 29, when Oxford Finance issued a notice of default under the company’s loan agreement and declared all obligations immediately due.&nbsp;On Oct. 19, Oxford informed Kala it intended to foreclose on all remaining assets,&nbsp;sweep all of the company’s cash, and&nbsp;restrict the use of funds to minimal payroll expenses necessary to execute the foreclosure. The same day, Kala terminated all remaining employees except those required to support Oxford’s process.Oxford later paused the foreclosure on Nov. 3 and allowed Kala to access $125,000 of previously swept cash to negotiate a potential transaction. On Nov.9, Kala executed a convertible loan agreement with investor David Lazar for $375,000 to fund&nbsp;the preparation of its quarterly filing and support negotiations for further investment.<h2 class="st-heading-2">Lifeline Private Placement Up To $6 Million</h2>The company then entered into a securities purchase agreement on Nov. 23 under which Lazar agreed to provide up to $6 million in a two-stage private placement of Series AA and Series AAA preferred stock. The first closing occurred on Monday, delivering $1.8 million to Kala. The second closing, for an additional $4.2 million, requires shareholder approval to increase authorized common shares and permit conversion of the preferred stock. Kala will hold the shareholder meeting before March 31, 2026. The proceeds will fund current operations, liabilities, and expenses, with $1 million of the second closing earmarked for Oxford as part of the settlement arrangement.<h2 class="st-heading-2">Settlement Restructures Obligations</h2>As part of the rescue package, Kala and unit Combangio entered into a loan settlement agreement with Oxford on Nov. 23. Oxford agreed to settle all outstanding payment obligations in exchange for a $2 million cash settlement and 1.62 million shares of common stock.&nbsp;Once Kala pays the initial $1 million and issues the settlement shares, Oxford will release control of Kala’s bank accounts, reduce the outstanding loan balance by $7 million, and waive associated interest and final payments. The company also agreed to pay Oxford 10% of future equity financing proceeds, up to $1 million, with each such payment reducing loan obligations by 3x the amount contributed.Oxford’s foreclosure efforts will formally end once the full settlement payment is completed. Kala is committed to pursuing a “material strategic alternative transaction” within one year to clear the remaining settlement balance.<h2 class="st-heading-2">Leadership Changes Accompany Restructuring</h2>As part of the financing deal, David Lazar was appointed CEO and elected to the board on Nov. 21. Lazar brings a turnaround-focused background to the role. He currently leads Custodian Ventures LLC and Activist Investing LLC, firms that specialize in turnaround situations involving distressed public companies.Todd Bazemore, the prior CEO, stepped down from the role but remains on the board. Meanwhile, chief financial officer Mary Reumuth was terminated effective immediately following the first closing, and the company also announced settlement agreements for certain former executives tied to their contractual severence rights.<h2 class="st-heading-2">Fallout From Eye Drug Trial Failure</h2>The crisis began in late September when KPI-012, a treatment for persistent corneal epithelial defect, failed to meet all primary and secondary endpoints in the Phase 2b CHASE trial. The miss contradicted the positive signals seen in the earlier Phase 1b trial and led management to terminate development of KPI-012 and its broader mesenchymal stem cell secretome platform. Analysts at Mizuho, H.C. Wainwright and LifeSci Capital downgraded the stock immediately afterward, citing the unexpected data and lack of disclosed details.&nbsp;<h2 class="st-heading-2">Stocktwits Users Cite David Lazar Upside For Kala Bio</h2>On Stocktwits, retail sentiment for Kala Bio was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/140;" src="https://news.stocktwits-cdn.com/kala_ss_png_9a4902a4d7.webp" alt="kala ss.png" width="970" height="140"><figcaption>KALA sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One bullish user said, “<a href="https://stocktwits.com/symbol/KALA">$KALA</a> 1.50 next leg. David Lazar play. new<a href="https://stocktwits.com/symbol/CETY"> $CETY</a>.”<stembedurl>https://stocktwits.com/CAPITALWHISPERER/message/637454686</stembedurl>Another user said, “Look what david Lazzar did to $opgen and find out why he make<a href="https://stocktwits.com/symbol/KALA"> $KALA</a> investors very rich if they are patient.”<stembedurl>https://stocktwits.com/Frederickquan/message/637468005</stembedurl><a href="https://stocktwits.com/symbol/KALA">Kala Bio’s stock</a> has declined 91% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio’s stock (KALA) has declined 91% so far in 2025. (Photo credit: Getty Images)

Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse

A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

KALA BIO (KALA) announced on Monday that its KPI-012 failed in a mid-stage clinical trial evaluating it as a treatment for persistent corneal epithelial defect.A persistent corneal epithelial defect (PCED) is a corneal injury that fails to heal within the typical timeframe of two weeks, persisting for weeks or even months despite standard treatment. Kala’s study to evaluate the safety and efficacy of two doses of KPI-012 ophthalmic solution did not meet the primary goal of complete healing of PCED at week 8, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.kalarx.com/news-releases/news-release-details/kala-bio-announces-topline-results-chase-phase-2b-clinical-trial">said</a>. It also noted that the secondary goals in the study did not achieve statistical significance, and there was no meaningful difference between the KPI-012 treatment arm and the placebo arm in the trial.The company subsequently decided to cease clinical development of KPI-012 and stated that it is evaluating its strategic options. The firm noted that it intends to preserve cash, including by laying off some of its workforce and implementing other cost-saving measures.Kim Brazzell, Chief Medical Officer of Kala Bio, said that the company is “disappointed” to see the new study results.“KPI-012 continued to be well-tolerated and demonstrated a favorable safety profile but did not demonstrate the efficacy results that would warrant advancing the program for treatment of front-of-the-eye diseases,” he added.Shares of the company slipped 89% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALA">KALA stock</a> rose to ‘extremely bullish’ from ‘neutral’ territory over the past 24 hours, while message volume rose to ‘extremely high’ from ‘high’ levels.Following the company’s announcement, LifeSci Capital downgraded Kala Pharmaceuticals to ‘Market Perform’ from ‘Outperform’ and removed the firm's price target on the stock.Mizuho analyst Graig Suvannavejh, meanwhile, expressed disappointment that the company did not share any data details or host a call to discuss the study results, as per TheFly. &nbsp;KALA stock is down by 69% this year and by about 62% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-stock-soars-pre-market-on-securing-license-for-cancer-related-pain-management-drug/chDubC3R3J2">Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Kala Bio Stock Just Plunged 89% Today – Here’s What Happened

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

Current Price	$0.171
Prev Close	$0.1757
Open	$0.18
Dividend Yield	0.00%
50-Day Moving Average	$0.386
Beta	0.85
Avg. Volume	657,001.57
PE Ratio	-0.03

52-Week High	$20.60
52-Week Low	$0.1607
Market Capitalization	$160.12M
EPS (Annual)	-$10.15
Price to Book	-0.15
Revenue Per Employee	$0.00

KALA
KALA BIO Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KALA News

KALAKALA BIO Inc